

TEAR HERE

**COMMON BID CUM APPLICATION FORM**

**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED - INITIAL PUBLIC OFFER - R**  
Registered and Corporate Office: D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana 500 003, India; Tel: +91 40 4418 6000;  
Website: www.kimshospitals.com; Contact Person: Umashankar Mantha, Company Secretary and Compliance Officer;  
E-mail: cs@kimshospitals.com; Corporate Identity Number: U55101TG1973PLC040558

**FOR RESIDENT INDIAN INVESTORS INCLUDING RESIDENT QIBs, NON-INSTITUTIONAL BIDDERS, RETAIL INDIVIDUAL BIDDERS AND ELIGIBLE NRIs APPLYING ON A NON-REPATRIATION BASIS**

**To,**  
**The Board of Directors**  
**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED**

**100% BOOK BUILT OFFER**  
**ISIN : INE967H01017**  
**LEI: 254900JA6LS4UY2ZCR81**

**Bid cum Application Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE		REGISTERED BROKER/SCSB/CDP/RTA STAMP & CODE		1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER	
				Mr./Ms./M/s. _____	
				_____	
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE		SCSB BRANCH STAMP & CODE		Address _____	
				_____ Email _____	
BANK BRANCH SERIAL NO.		SCSB SERIAL NO.		Tel. No. (with STD code) / Mobile _____	
				2. PAN OF SOLE / FIRST BIDDER	
				_____	

**3. BIDDER'S DEPOSITORY ACCOUNT DETAILS**    ☐ NSDL    ☐ CDSL

For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

**4. BID OPTIONS (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")**

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1 only) (In Figures only)												"Cut-off" (Please ✓ tick)
									Bid Price				Retail Discount				Net Price				
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1				
Option 1																					<input type="checkbox"/>
(OR) Option 2																					<input type="checkbox"/>
(OR) Option 3																					<input type="checkbox"/>

**5. CATEGORY**  
☐ Retail Individual Bidder  
☐ Non-Institutional Bidder  
☐ QIB

**6. INVESTOR STATUS**  
☐ Individual(s) - IND  
☐ Hindu Undivided Family - HUF\*  
☐ Bodies Corporate - CO  
☐ Systemically Important NBFCs  
☐ Banks & Financial Institutions - FI  
☐ Mutual Funds - MF  
☐ National Investment Fund - NIF  
☐ Insurance Funds - IF  
☐ Insurance Companies - IC  
☐ Venture Capital Fund - VCF  
☐ Alternative Investment Fund - AIF  
☐ Other QIBs - OTH  
☐ Non Resident Indian - NRI (Non repatriation basis)  
☐ All entities other than QIBs, Bodies Corporates and Individuals - NOH  
Please Specify \_\_\_\_\_  
\*HUF should apply only through Karta (Application by HUF would be treated on par with individual).

**7. PAYMENT DETAILS [IN CAPITAL LETTERS]**

Amount blocked (₹ in figures) \_\_\_\_\_ (₹ in words) \_\_\_\_\_

**ASBA** \_\_\_\_\_  
Bank A/c No. \_\_\_\_\_  
Bank Name & Branch \_\_\_\_\_  
OR  
UPI ID (Maximum 45 characters) \_\_\_\_\_

**PAYMENT OPTION : FULL PAYMENT** ☒

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE COMMON BID CUM APPLICATION FORM GIVEN OVERLEAF.

**8A. SIGNATURE OF SOLE/ FIRST BIDDER**  
\_\_\_\_\_  
Date : \_\_\_\_\_, 2021

**8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S)  
(AS PER BANK RECORDS)**  
I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.  
1) \_\_\_\_\_  
2) \_\_\_\_\_  
3) \_\_\_\_\_

**MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)**  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

TEAR HERE

**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED**  
**INITIAL PUBLIC OFFER - R**

**Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent**

**Bid cum Application Form No.**

DPID / CLID \_\_\_\_\_

Amount blocked (₹ in figures) \_\_\_\_\_ ASBA Bank A/c No./UPI ID \_\_\_\_\_

Bank Name & Branch \_\_\_\_\_

Received from Mr./Ms./M/s. \_\_\_\_\_

Telephone / Mobile \_\_\_\_\_ Email \_\_\_\_\_

**PAN of Sole / First Bidder** \_\_\_\_\_

**Stamp & Signature of SCSB Branch**  
\_\_\_\_\_  
\_\_\_\_\_

TEAR HERE

**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED - INITIAL PUBLIC OFFER - R**

	Option 1	Option 2	Option 3
No. of Equity Shares			
Bid Price			
Amount Blocked (₹ in figures)			

**Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent**  
\_\_\_\_\_  
\_\_\_\_\_

**Name of Sole / First Bidder**  
\_\_\_\_\_  
\_\_\_\_\_

**Acknowledgement Slip for Bidder**  
**Bid cum Application Form No.**

ASBA Bank A/c No./UPI ID \_\_\_\_\_  
Bank Name & Branch \_\_\_\_\_

Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS  
DATED JUNE 9, 2021, (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

**BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM**

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of RHP dated June 9, 2021, filed with the Registrar of Companies, Andhra Pradesh and Telangana at Hyderabad (the "RoC") (if I am/we are in India) or the preliminary international wrap dated June 9, 2021, together with the RHP (the "Preliminary Offering Memorandum") (if I am/we are outside India), General Information Document for Investing in Public Offers ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer upto my/our Bids for maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID (in case of Retail Individual Bidders ("RIBs") using UPI Mechanism) as mentioned in the Bid Cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, the Bid Cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only (i) the SCSBs (for Bids other than the Bids by Anchor Investors) and (ii) the Book Running Lead Managers (the "BRLMs") and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid Cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and RIBs based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP. I/we authorise the Company to make the necessary changes in this Bid Cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid Cum Application Form as the application form for the purpose of this Offer. I/we confirm that I/we have read the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India).

**I/WE CONFIRM THAT:** EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign nationals OR I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account on non-repatriation basis. I/we and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares confirm that I am/we are, or at any time the Equity Shares are purchased will be, the beneficial owner of such Equity Shares. I/we and any customer I/we represent (A) am/are either (i) located outside the United States and I am/we are purchasing the Equity Shares in an "offshore transaction" meeting the requirements of Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and the applicable laws of the jurisdiction where such offer and sale is made or (ii) a "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A") purchasing the Equity Shares in transactions meeting the requirements of Rule 144A or another exemption from the registration requirements of the U.S. Securities Act, (B) I/we have received a copy of the RHP (if we are in India) or the Preliminary Offering Memorandum (if we are outside India) and that my/our investment decision is based solely on the RHP or the Preliminary Offering Memorandum, as applicable, (C) I/we have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures - Eligibility and Transfer Restrictions" on page 363 of the RHP and, where applicable, the sections "Distribution and Solicitation Restrictions" and "Transfer Restrictions" of the Preliminary Offering Memorandum, and (D) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate. This Bid Cum Application Form is being issued to you on basis that you (i) agree to abide by (1) this Bid Cum Application Form and (2) the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India), together with the terms and conditions contained therein.

**FOR QIB BIDDERS:** I/we confirm that the Bid size/maximum Equity Shares applied for by me/us do not exceed the relevant regulatory approvals/limits. I am/We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

**Further:** 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or the RTAs (at the Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSB as specified in the Bid Cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid Cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Bank, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB/Registrar to the Offer shall reject the application. 3) I/we hereby authorise the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band. I/we hereby provide my/our consent to the Stock Exchanges / Sponsor Banks / NPCI / Registrar to the Offer for collecting, storing and usage validating my/our PAN details from the bank account where my /our amount is blocked by the relevant SCSBs.

I/We acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/We are not an OCB. For further details, see "Offer Procedure" and "Restrictions on Foreign Ownership of Indian Securities" on pages 381 and 396 respectively of the RHP.

**INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM**

1. Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an Offer" during the Bid/ Offer period by a Bidder and not "an Offer".

2. The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim and any other category of Bidders including without limitation, multilateral/bilateral institution, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above.

3. Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking of ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment of Equity Shares, delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer or RTAs/CDPs or the SCSBs nor the Company nor the Selling Shareholders shall have any responsibility and undertake any liability for the same.

4. **Bid Lot and Price Band:** The face value of Equity Shares is ₹ 10/- each. The Price Band and the minimum Bid Lot have been decided by the Company in consultation with the BRLMs and will be advertised in all editions of Business Standard, an English national daily newspaper, all editions of Business Standard, a Hindi national daily newspaper and Hyderabad edition of Surya, a Telugu newspaper, Telugu being the regional language of Telangana, where our Registered and Corporate Office is located, each with wide circulation, at least two (2) Working Days prior to the Bid/ Offer Opening Date and have been made available to BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges" for the purpose of uploading on their respective websites in accordance with SEBI ICDR Regulations. In case of any revision to the Price Band, the Bid/ Offer Period will be extended, by at least three (3) additional Working Days after such revision of the Price Band, subject to the Bid/ Offer Period not exceeding ten (10) Working Days. In case of a force majeure, banking strike or similar circumstances, the Company may, in consultation with the BRLMs, may for reasons to be recorded in writing extend the Bid/ Offer Period for minimum three (3) working days subject to the Bid/ Offer Period not exceeding ten (10) working days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the changes on the respective websites of the BRLMs and on the terminals of the Syndicate Member and by intimation to the Designated Intermediaries and the Sponsor Bank, as applicable.

5. **Maximum and Minimum Bid Size:** In case of RIBs, such number of Equity Shares in multiples of the minimum Bid Lot such that the Bid Amount does not exceed ₹ 200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and RIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP or Preliminary Offering Memorandum.

6. Please tick Category as applicable to ensure proper upload of Bid in Stock Exchange system.

7. Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.

8. **Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRI bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of RIBs Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid Cum Application Form from the Registered and Corporate Office of the Company or from the Syndicate Member or CDPs or RTAs or Registered Brokers from the Bidding Centres. In accordance with applicable law and UPI Circulars, Bidders to please ensure that SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.

9.
  - Please note that application made using third party UPI ID or third party ASBA Bank A/c. are liable to be rejected.
  - QIBs and Non-Institutional Investors cannot use UPI Mechanism to apply.
  - **For RIBs applying using UPI.**
    - Please ensure that your Bank is offering UPI facility for Public Offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - **Ensure that the:** (a) bank where the bank account linked to their UPI ID is maintained; and (b) RIBs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=43>) respectively, as updated from time to time.
    - **Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid Cum Application Form.**
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - **RIBs Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN.**
- For further details, see "Offer Procedure" on page 381 of the RHP.

10. Only the First Bidder is required to sign the Bid cum Application Form (Revision Form). Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.

11. **Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.

12. The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected.

13. The Equity Shares have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act and referred to in the Red Herring Prospectus as "U.S. QIBs") in transactions exempt from the registration requirements of the U.S. Securities Act and (b) outside the United States in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

You may send the RHP (if you are in India) or the Preliminary Offering Memorandum and the Final Offering Memorandum (if you are outside India) either in physical form or electronic form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in or accompanying them.

**Note:** Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLMs and the Stock Exchanges.

TEAR HERE

- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer.
- In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB.
- In case of queries related to upload of Bids submitted to the relevant member of the Syndicate / RTAs / Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.
- For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail Id:- [ipoupi@npci.org.in](mailto:ipoupi@npci.org.in) ; HDFC Bank Limited at Tel: 022-30752927/28/2914 and E-mail: [Vincent.Dsouza@hdfcbank.com](mailto:Vincent.Dsouza@hdfcbank.com) / [siddharth.jadhav@hdfcbank.com](mailto:siddharth.jadhav@hdfcbank.com) / [prasanna.uchil@hdfcbank.com](mailto:prasanna.uchil@hdfcbank.com); and the Registrar to the Offer at Tel: +91 22 4918 6200 and E-mail: [kims ipo@linkintime.com](mailto:kims ipo@linkintime.com)

**COMPANY CONTACT DETAILS**

**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED**  
**Registered and Corporate Office:**  
D. No. 1-8-31/1, Minister's Road,  
Secunderabad – 3, Telangana 500 003, India;  
**Tel:** +91 40 4418 6000; **Website:** [www.kimshospitals.com](http://www.kimshospitals.com);  
**Contact Person:** Umashankar Mantha, Company Secretary and  
Compliance Officer;  
**E-mail:** [cs@kimshospitals.com](mailto:cs@kimshospitals.com);  
**Corporate Identity Number:** U55101TG1973PLC040558

**REGISTRAR TO THE OFFER CONTACT DETAILS**

**Link Intime India Private Limited**  
C-101, 247 Park, L B S Marg, Vikhroli (West)  
Mumbai 400 083, Maharashtra, India  
**Tel:** +91 22 4918 6200  
**E-mail:** [kims ipo@linkintime.com](mailto:kims ipo@linkintime.com)  
**Website:** [www.linkintime.co.in](http://www.linkintime.co.in)  
**Investor grievance ID:** [kims ipo@linkintime.com](mailto:kims ipo@linkintime.com)  
**Contact Person:** Shanti Gopalkrishnan  
**SEBI Registration Number:** INR000004058

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

This is an abridged prospectus containing salient features of the red herring prospectus dated June 9, 2021 (the "RHP"). You are encouraged to read greater details available in the RHP. Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

**THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONGWITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Please ensure that you have read the RHP, this abridged prospectus ("Abridged Prospectus") and the general information document for investing in public offers ("GID") undertaken through the Book Building Process before applying in the Offer (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the Stock Exchanges (as defined below), Members of the Syndicate, Registered Brokers, Collecting Depository Participants ("CDPs"), Registrar to the Offer, Registrar and Share Transfer Agents ("RTAs"), Bankers to the Offer, or Self Certified Syndicate Banks ("SCSBs"). You may also download the RHP from the websites of the Securities and Exchange Board of India ("SEBI") at [www.sebi.gov.in](http://www.sebi.gov.in), the Stock Exchanges where the Equity Shares (as defined below) are proposed to be listed, i.e., BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges") at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com); respectively and the Book Running Lead Managers ("BRLMs") at [www.investmentbank.kotak.com](http://www.investmentbank.kotak.com), [www.axiscapital.co.in](http://www.axiscapital.co.in), <https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html> and [www.iifcap.com](http://www.iifcap.com). This Abridged Prospectus may only be accessed by investors outside of India that have read the Preliminary Offering Memorandum of the Company dated June 9, 2021, a copy of which is available to eligible investors from the BRLMs.



## KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

Our Company was incorporated as 'Jagjit Singh and Sons Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai on July 26, 1973. Our Company changed the location of its registered office from the State of Maharashtra to the erstwhile State of Andhra Pradesh, pursuant to an order dated January 29, 2003 by the Company Law Board, Western Region Bench, Mumbai ("Order") and the registration of the Order vide certificate of registration dated February 21, 2003 by the Registrar of Companies, Andhra Pradesh and Telangana (then the Registrar of Companies, Andhra Pradesh) ("RoC"). Subsequently, the name of our Company was changed to 'Krishna Institute of Medical Sciences Private Limited', pursuant to a letter of approval from the Central Government dated January 2, 2004 and a fresh certificate of incorporation issued by the RoC on January 2, 2004. Further, pursuant to the conversion of our Company to a public limited company, our name was changed to 'Krishna Institute of Medical Sciences Limited' and the RoC issued a fresh certificate of incorporation on January 29, 2004. For further details, see "History and Certain Corporate Matters" on page 198 of the RHP.

**Registered and Corporate Office:** D. No. 1-8-31/1, Minister's Road, Secunderabad – 3, Telangana 500 003, India; Tel: +91 40 4418 6000; **Website:** [www.kimshospitals.com](http://www.kimshospitals.com);

**Contact Person:** Umashankar Mantha, Company Secretary and Compliance Officer; **E-mail:** [cs@kimshospitals.com](mailto:cs@kimshospitals.com); **Corporate Identity Number:** U55101TG1973PLC040558

### OUR PROMOTERS: DR. BHASKARA RAO BOLLINENI, RAJYASRI BOLLINENI, DR. ABHINAV BOLLINENI, ADWIK BOLLINENI AND BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 2,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 23,560,538 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER FOR SALE"), COMPRISING UP TO 16,003,615 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY GENERAL ATLANTIC SINGAPORE KH PTE. LTD (THE "INVESTOR SELLING SHAREHOLDER"), UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY DR. BHASKARA RAO BOLLINENI, UP TO 775,933 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY RAJYASRI BOLLINENI, UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED (COLLECTIVELY, THE "PROMOTER SELLING SHAREHOLDERS"), 6,005,058 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY PERSONS REFERRED TO IN ANNEXURE A (REFERRED TO AS THE "OTHER SELLING SHAREHOLDERS", TOGETHER WITH THE INVESTOR SELLING SHAREHOLDER AND PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES THE "OFFERED SHARES").

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES, AGGREGATING UP TO ₹ 200.00 MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY THE BOARD OF DIRECTORS OF OUR COMPANY ("OUR BOARD") OR THE IPO COMMITTEE, AS APPLICABLE, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF BUSINESS STANDARD (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), AND ALL EDITIONS OF BUSINESS STANDARD (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND HYDERABAD EDITION OF SURYAA (A WIDELY CIRCULATED TELUGU DAILY NEWSPAPER) (TELUGU BEING THE REGIONAL LANGUAGE IN THE STATE WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSES OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the members of the Syndicate and by an intimation to Designated Intermediaries and the Sponsor Bank, as applicable. The Equity Shares offered through the RHP are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to letters dated March 23, 2021 and March 24, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE.

### PROCEDURE

If you wish to know about processes and procedures applicable to public issues, you may request for a copy of the GID from the BRLMs or download it from the websites of the Stock Exchanges at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) or from the websites of the BRLMs at [www.investmentbank.kotak.com](http://www.investmentbank.kotak.com), [www.axiscapital.co.in](http://www.axiscapital.co.in), <https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html> and [www.iifcap.com](http://www.iifcap.com).

### ELIGIBILITY FOR THE OFFER

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), as amended through the Book Building Process and in compliance with Regulation 6(2) of the SEBI ICDR Regulations. Whether the Company is compulsorily required to allot at least 75% of the Net Offer to Qualified Institutional Buyers – Yes

### INDICATIVE TIMELINE

<b>BID/ OFFER OPENS ON<sup>(1)</sup></b>	Wednesday, June 16, 2021	<b>Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account*</b>	On or about Thursday, June 24, 2021
<b>BID/ OFFER CLOSES ON<sup>(2)</sup></b>	Friday, June 18, 2021	<b>Credit of Equity Shares to demat accounts of Allottees</b>	On or about Friday, June 25, 2021
<b>Finalisation of Basis of Allotment with the Designated Stock Exchange</b>	On or about Wednesday, June 23, 2021	<b>Commencement of trading of the Equity Shares on the Stock Exchanges</b>	On or about Monday, June 28, 2021

(1) Our Board or the IPO Committee, as applicable, may in consultation with the Book Running Lead Managers, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date in accordance with the SEBI ICDR Regulations. (2) UPI mandate end time and date shall be at 12:00 pm on Monday, June 21, 2021 \* In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding four Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of ₹100 per day for the entire duration of delay exceeding four Working Days from the Bid/Offer Closing Date by the intermediary responsible for causing such delay in unblocking. The Book Running Lead Managers shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. Further, investors shall be entitled to compensation in the manner specified in the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 read with SEBI circular number SEBI/HO/CFD/DIL1/CIR/P/2021/47 dated March 31, 2021 in case of delays in resolving investor grievances in relation to blocking/unblocking of funds. For avoidance of doubt, the provisions of the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 read with the SEBI Circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 shall be deemed to be incorporated in the deemed agreement between the Company and the SCSBs to the extent applicable.



**GENERAL RISKS**

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the RHP. Specific attention of the investors is invited to “Risk Factors” beginning on page 28 of the RHP, and “Internal Risk Factors” on page 7 of this Abridged Prospectus.

**PRICE INFORMATION OF BRLMs**

S. No.	Issue name	Name of the merchant banker	+/- % change in closing price, +/- % change in closing benchmark]- 30 <sup>th</sup> calendar days from listing	+/- % change in closing price, +/- % change in closing benchmark]- 90 <sup>th</sup> calendar days from listing	+/- % change in closing price, +/- % change in closing benchmark]- 180 <sup>th</sup> calendar days from listing
1	Macrotech Developers Limited	Kotak, Axis, IIFL	+30.22%, [+5.21%]	Not Applicable	Not Applicable
2	Barbeque – Nation Hospitality Limited	Axis, IIFL	+18.77%, [-0.64%]	Not Applicable	Not Applicable
3	Suryoday Small Finance Bank Limited	Axis, IIFL	-18.38%, [-1.14%]	Not Applicable	Not Applicable
4	Kalyan Jewellers India Limited#	Axis	-24.60%, [-1.14%]	Not Applicable	Not Applicable
5	Craftsman Automation Limited	Axis, IIFL	-13.82%, [+0.11%]	Not Applicable	Not Applicable
6	Laxmi Organic Industries Limited	Axis	+37.85%, [+0.11%]	Not Applicable	Not Applicable
7	Anupam Rasayan India Limited	Axis, IIFL	-0.11%, [-0.98%]	Not Applicable	Not Applicable
8	Nazara Technologies Ltd	IIFL	+62.57%, [+0.13%]	Not Applicable	Not Applicable
9	MTAR Technologies Limited	IIFL	+69.45%, [-2.84%]	Not Applicable	Not Applicable
10	Home First Finance Company India Limited	Kotak, Credit Suisse	+4.98%, [+1.97%]	-5.64%, [-1.05%]	Not Applicable
11	Indigo Paints Limited	Kotak	+75.72%, [+4.08%]	+55.40%, [-0.11%]	Not Applicable
12	Burger King India Limited	Kotak	+146.50%, [+7.41%]	+135.08%, [+10.86%]	Not Applicable
13	Gland Pharma Limited	Kotak	+48.43%, [+7.01%]	+57.27%, [+18.27%]	+104.17%, [+17.49%]
14	UTI Asset Management Company Limited	Kotak	-10.43%, [+5.87%]	-0.60%, [+20.25%]	+5.81%, [+24.34%]
15	Computer Age Management Services Limited	Kotak	+5.43%, [+2.37%]	+49.52%, [+23.04%]	+43.80%, [+26.65%]
16	Sterling and Wilson Solar Limited	Credit Suisse	-21.88%, [-1.60%]	-48.63%, [+7.97%]	-64.78%, [+9.95%]
17	Metropolis Healthcare Limited	Credit Suisse	+3.75%, [-4.01%]	21.39%, [-1.18%]	45.93%, [-3.30%]

**Notes:** 1. Disclosures subject to recent 7 issues (initial public offerings) in current financial year and two preceding financial years managed by each BRLM with common issues disclosed once.; 2. For Kotak 30th, 90th, 180th calendar days from listed day have been taken as listing day plus 29, 89 and 179 calendar days. 3. For Credit Suisse 30th, 90th, 180th calendar days from listed day have been taken as listing day plus 29, 89 and 179 calendar days; 4. For IIFL 30th, 90th and 180th calendar day from listed day have been taken as listing day plus 29, 89 and 179 calendar days; 5. In case the 30th /60th /90th calendar day is a holiday, data from previous trading day has been considered. 6. Nifty is considered as the benchmark index except for Computer Age Management Services Limited where SENSEX is considered as benchmark index.; 7. Not applicable – where the relevant period has not been completed.

For further details, please refer to price information of past issued handled by BRLMs on page 367-371 of the RHP respectively.

**BOOK RUNNING LEAD MANAGERS**

<b>Kotak Mahindra Capital Company Limited</b> Telephone: + 91 22 4336 0000 E-mail: kims.ipo@kotak.com Investor grievance E-mail: kmccredressal@kotak.com	<b>Axis Capital Limited</b> Telephone: + 91 22 4325 2183 E-mail: kims.ipo@axiscap.in Investor grievance E-mail: complaints@axiscap.in	<b>Credit Suisse Securities (India) Private Limited</b> Telephone: + 91 22 6777 3777 E-mail: list.kimsipo@credit-suisse.com Investor grievance E-mail: list.igcellmerbnkg@credit-suisse.com	<b>IIFL Securities Limited</b> Tel: +91 22 4646 4600 E-mail: kims.ipo@iiflcap.com Investor grievance E-mail: ig.ib@iiflcap.com
---	--	--	---

<b>Name of Syndicate Member</b>	<b>Kotak Securities Limited</b>
<b>Registrar to the Offer</b>	<b>Link Intime India Private Limited</b> Telephone: +91 22 4918 6200; E-mail: kims.ipo@linkintime.com; <b>Investor grievance E-mail:</b> kims.ipo@linkintime.com
<b>Statutory Auditor</b>	<b>S. R. Batliboi &amp; Associates LLP, Chartered Accountants</b>
<b>Name of Credit Rating Agency and grading obtained, Debenture Trustee</b>	Not Applicable
<b>Self Certified Syndicate Banks</b>	The list of SCSBs notified by SEBI for the ASBA process is available at <a href="http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes">http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes</a> , or at such other website as may be prescribed by SEBI from time to time. A list of the Designated SCSB Branches with which an ASBA Bidder (other than a RIB using the UPI Mechanism), not bidding through Syndicate/ Sub Syndicate or through a Registered Broker, RTA or CDP may submit the Bid cum Application Forms, is available at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34</a> , or at such other websites as may be prescribed by SEBI from time to time.
<b>Registered Brokers</b>	The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the website of BSE and the NSE at <a href="http://www.bseindia.com">http://www.bseindia.com</a> and <a href="https://www.nseindia.com">https://www.nseindia.com</a> , respectively, as updated from time to time.
<b>Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable:</b>	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, is provided on the websites of Stock Exchanges at <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a> and at the website of SEBI at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34</a> . The list comprising the details of branches of the SCSBs at the Broker Centres, named by the respective SCSBs to receive deposits of the Bid cum Application Forms from the Registered Brokers will be available on the website of the SEBI at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmId=34</a> , and updated from time to time. For further details, see “Offer Procedure” on page 381 of the RHP.

## **PROMOTERS OF OUR COMPANY**

**The Promoters of our Company are:** Dr. Bhaskara Rao Bollineni; Dr. Abhinay Bollineni; Adwik Bollineni; Rajyasri Bollineni; and Bollineni Ramanaiah Memorial Hospitals Private Limited.

### **Details of our Promoters:**

- Dr. Bhaskara Rao Bollineni** : Dr. Bhaskara Rao Bollineni, born on January 01, 1954, aged 67 years, is a citizen of India. He is also the Managing Director of our Company and has over 27 years of experience in cardiothoracic surgery.
- Rajyasri Bollineni** : Rajyasri Bollineni, born on August 21, 1959, aged 61 years, is a citizen of India. She is currently the chairman of Aditya Educational Society and a director of Hyderabad Institute of Medical Sciences Association.
- Dr. Abhinay Bollineni** : Dr. Abhinay Bollineni, born on February 14, 1988, aged 33 years, is a citizen of India. He is also an executive Director and the CEO of our Company. He played a key role in establishing KIMS Kondapur in 2014.
- Adwik Bollineni** : Adwik Bollineni, born on April 27, 1992, aged 29 years, is a citizen of India. He is the Vice President - Strategy and Acquisition of our Company. He is currently on the governing board of Aditya Educational Society as the secretary.
- Bollineni Ramanaiah Memorial Hospitals Private Limited ("BRMH")** : BRMH was incorporated on January 8, 1999 at Hyderabad (Andhra Pradesh) as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation issued by Registrar of Companies, Andhra Pradesh at Hyderabad.

For details in respect of their date of birth, age, personal address, educational qualifications, experience in the business, positions and posts held in the past, business and financial activities, other directorships and special achievements, if any, see **"Our Management"** and **"Our Promoters and Promoter Group"** beginning on page 207 and page 223 respectively, of the RHP.

## **OUR BUSINESS OVERVIEW AND STRATEGY**

**Business Overview** : We are one of the largest corporate healthcare groups in AP and Telangana in terms of number of patients treated and treatments offered, according to the CRISIL Report commissioned by us. We provide multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care in Tier 2-3 cities and primary, secondary, tertiary and quaternary healthcare in Tier 1 cities. We operate 9 multi-specialty hospitals under the "KIMS Hospitals" brand, with an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021, which is 2.2 times more beds than the second largest provider in AP and Telangana, according to the CRISIL Report commissioned by us. We offer a comprehensive range of healthcare services across over 25 specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & child care.

**COMPETITIVE STRENGTHS** : 1) Regional leadership driven clinical excellence and affordable healthcare; 2) Ability to attract, train and retain high quality doctors, consultants and medical support staff; 3) Track record of strong operational and financial performance; 4) Well positioned to consolidate in India's large, unorganized yet rapidly growing and underserved affordable healthcare market; 5) Disciplined approach to acquisitions resulting in successful inorganic growth; 6) Experienced senior management team with strong institutional shareholder support.

**OUR STRATEGIES** : 1) Strengthen our existing hospitals and specialties; 2) Strategically grow our presence in adjacent markets; 3) Implementation of initiatives to improve existing operational efficiencies; 4) Invest in digital health care and technology.

## **BOARD OF DIRECTORS**

<b>Sr. No.</b>	<b>Name</b>	<b>Designation</b>	<b>Experience including current/past position held in other firms</b>
1	Dr. Bhaskara Rao Bollineni	Managing Director	He has over 27 years of experience in cardiothoracic surgery and has in the past held various positions with Apollo Hospitals, Austin Hospital, University of Melbourne and Mahavir Hospital and Research Centre.
2	Anitha Dandamudi	Whole-time Director	She has over 16 years of experience in the hospital industry, having held various positions with our Company, and has also served as vice president of administration at e-Talent Software Limited.
3	Dr. Abhinay Bollineni	Executive Director	He participated in 'International Visitor Leadership Program on Oncology: Research, Prevention and Treatment' held by U.S. Department of State where he undertook training in diagnosis, treatment methods, and follow-up care for cancer patients and their families. Additionally, he played key role in establishing KIMS Kondapur in 2014.
4	Sandeep Naik	Non-executive Director	He is a Managing Director and head of General Atlantic's business in India and Asia-Pacific. He was previously associated with Apax Partners LP, and McKinsey and Company. He was also selected as a Young Global Leader by the World Economic Forum in 2010.
5	Shantanu Rastogi	Non-executive Director	He is a Managing Director at General Atlantic. He was previously associated with Apax Partners India Advisers Private Limited and McKinsey and Company.
6	Pankaj Vaish	Independent Director	He has over 35 years of experience in various fields, including 28 years of experience with Accenture Services Private Limited (Accenture). He was also a member of the global leadership team of the 'Communications, Media and Technology' (CMT) business of Accenture.
7	Rajeswara Rao Gandu	Independent Director	He has over 37 years of experience as a civil servant and has worked in the Department of Supply, GoI in the past. He joined the Indian Revenue Service thereafter, where he held various positions.
8	Ratna Kishore Kaza	Independent Director	He has held the position of Principal Secretary (health, medical and family welfare) to the Government of Andhra Pradesh and has served as an Administrative Member on the Andhra Pradesh Administrative Tribunal.
9	Saumen Chakraborty	Independent Director	He has more than 36 years of experience across various strategic and operational aspects of management. He was previously employed with Dr. Reddy's Laboratories Limited for over 19 years, where he held various positions.
10	Venkata Ramudu Jasthi	Independent Director	He is a member of batch of 1981 of the Indian Police Service cadre of Andhra Pradesh and has held the position of the Director General of Police of Andhra Pradesh.

For further details in relation to our Board of Directors, see **"Our Management"** on page 207 of the RHP.

**OBJECTS OF THE OFFER**

The Offer comprises a Fresh Issue of up to [●] Equity Shares, aggregating up to ₹ 2,000.00 million by our Company and an Offer for Sale of up to 23,560,538 Equity Shares, aggregating up to ₹ [●] million by the Selling Shareholders.

**Net Proceeds**

The details of the Net Proceeds are summarised in the table below:

(in ₹ million)

Particulars	Estimated Amount
Gross proceeds of the Fresh Issue	2,000.00
(Less) Offer expenses to the extent applicable to the Fresh Issue (only those apportioned to our Company)*	[●]**
<b>Net Proceeds</b>	<b>[●]**</b>

\*See “ - Offer Related Expenses” on page 105 of the RHP.

\*\*To be finalized upon determination of the Offer Price.

**Proposed Schedule of Implementation and Deployment of Net Proceeds**

The Net Proceeds are to be deployed in accordance with the schedule set forth below:

(in ₹ million)

Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds
		Fiscal 2022
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and our Subsidiaries viz KHKPL, SIMSPL and KHEPL	1,500.00	1,500.00
General corporate purposes*	[●]	[●]
<b>Total</b>	<b>[●]</b>	<b>[●]</b>

\*To be finalised upon determination of Offer Price. The amount utilised for general corporate purposes shall not exceed 25% of the Net Proceeds.

**Means of Finance :** The fund requirements for the Objects are proposed to be entirely funded from the Net Proceeds. In case of a shortfall in raising requisite capital from the Net Proceeds, business considerations may require us to explore a range of options including utilising our internal accruals. We expect that such alternate arrangements to be available to fund any such shortfalls.

**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public issues / rights issues, if any, of the Company in the preceding 10 years:** Not Applicable

**Terms of Issuance of Convertible Security, if any:** Not Applicable

**Name of Monitoring Agency:** The Federal Bank Limited

**Shareholding Pattern as on the date of the RHP:**

Category of shareholder	Number of fully paid up equity shares held	Shareholding as a % of total number of shares
<b>Promoter and Promoter Group</b>	3,63,23,850	46.81
<b>Public</b>	4,12,69,433	53.19
<b>Total</b>	<b>7,75,93,283</b>	<b>100%</b>

**Number of Equity Shares proposed to be sold by Selling Shareholders:**

Dr. Bhaskara Rao Bollineni (387,966 Equity Shares), Rajyasri Bollineni (775,933 Equity Shares), Bollineni Ramanaiah Memorial Hospitals Private Limited (387,966 Equity Shares), General Atlantic Singapore KH Pte. Ltd. (16,003,615 Equity Shares), Seenaiah Bollineni (1,163,899 Equity Shares), Bollineni Aishwarya (2,521,782 Equity Shares), PVN Raju (4,000 Equity Shares), Jwala Srikala Mulugu (7,000 Equity Shares), Mulukutla Sambasiva Sastry (2,000 Equity Shares), K Kalyana Chowdary (2,850 Equity Shares), Darshan Jayantilal Rathod (4,000 Equity Shares), Vaka Krishna Sree (22,500 Equity Shares), Hygriv Rao Bhaganagarapu (2,000 Equity Shares), Konduri Rajender Nath (2,500 Equity Shares), Rajendra Kumar Premchand (568,000 Equity Shares), Sasikala Vasthimal (46,945 Equity Shares), Rajendrakumar Premchand Shah (HUF) (37,889 Equity Shares), Naresh Rajendra Shah (18,200 Equity Shares), Sahariah Sarbeswar (87,624 Equity Shares), Dr. V. S. V. Prasad (178,856 Equity Shares), V S Srinath (63,812 Equity Shares), T N C Padmanabhan (39,336 Equity Shares), Sudhakar Kanthamaneni (100,000 Equity Shares), Sitaram Prasad Gogineni (261,202 Equity Shares), Venkata Krishna Kumar Kodali (50,000 Equity Shares), Gavini Satyanarayana (20,000 Equity Shares), Gavini Jayanthi (20,000 Equity Shares), Srivalli Marakathamani (65,113 Equity Shares), Meka Yanadi Naidu (4,000 Equity Shares), Krishna Rao Inturi (5,000 Equity Shares), Raghu Rama Pillarisetty (192,960 Equity Shares), S Vyjayanthi (35,000 Equity Shares), Kotha Usha Lakshmi Kumari (1,460 Equity Shares), Vijay Kumar Devraj (20,000 Equity Shares), Doppalapudi Pooja Lakshmi (36,660 Equity Shares), K Ch Subba Rao (119,935 Equity Shares), Rama Devi Kolla (28,000 Equity Shares), Kolla Sridevi (20,000 Equity Shares), Srikanth Kolla (36,000 Equity Shares), N.S. Ramaraju (40,000 Equity Shares), Atluri Naaga Deepthi (60,000 Equity Shares), Praveen Mallikarjuna Mulukuntla (1,000 Equity Shares), Pyar Ali A Jiwani (40,000 Equity Shares), Ravikanth Garipalli (30,000 Equity Shares), Thota Narendar Kumar (3,035 Equity Shares), G Rajender (2,500 Equity Shares), C. Naresh Kumar Reddy (10,000 Equity Shares) and Bala Padmaja Chowdary (30,000 Equity Shares).

**RESTATED FINANCIAL STATEMENTS**

**Summary of Restated Consolidated Financial Information**

(Figure in Rupees Millions, unless otherwise stated)

Particulars	As at and for the Financial Year ended March 31, 2021	As at and for the Financial Year ended March 31, 2020	As at and for the Financial Year ended March 31, 2019
Total income	13,401.02	11,287.28	9,238.69
Profit/ (loss) before tax expense	2,790.15	1,405.26	(153.81)
Profit /(loss) for the year	2,054.79	1,150.72	(488.07)
Equity Share capital	775.93	744.90	744.90

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Particulars	As at and for the Financial Year ended March 31, 2021	As at and for the Financial Year ended March 31, 2020	As at and for the Financial Year ended March 31, 2019
Other Equity	7,861.41	5,236.35	4,661.70
Net worth (equity attributable to the owners) <sup>(1)</sup>	8,637.34	5,981.25	5,406.60
Basic earnings per share (Rs.) <sup>(2)</sup>	26.87	16.00	(6.91)
Diluted earnings per share (Rs.) <sup>(3)</sup>	26.42	15.87	(6.91)
Return on Net worth (%) <sup>(4)</sup>	23.30%	19.93%	(8.84%)
Net asset value per Equity Share (basic) (in ₹) <sup>(5)(6)</sup>	115.36	80.30	78.18

**Notes:** 1. Net worth = total equity attributable to owners of the Company; 2. Basic EPS = Restated profit / (loss) attributable to equity shareholders of the Company divided by weighted average number of equity shares outstanding during the year - basic; 3. Diluted EPS = Restated profit / (loss) attributable to equity shareholders of the Company divided by weighted average number of equity shares outstanding during the year - diluted; 4. Return on Net Worth = Profit/ (loss) attributable to: owners of the Company divided by total equity attributable to owners of the Company; 5. Net asset value per equity share (₹) = Total equity attributable to owners of the Company divided by weighted average number of equity shares outstanding during the year; 6. Our net asset value reflects our results of operations after making certain adjustments. For more information, see "Other Financial Information" on page 311 of the RHP.

## INTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP:

- 1) We are highly dependent on our healthcare professionals, including doctors that we engage on a consultancy basis, and our business and financial results could be impacted if we are not able to attract and retain such healthcare professionals.
- 2) The COVID-19 pandemic has affected our regular business operations and may continue to do so, depending on the severity and duration of the COVID-19 pandemic.
- 3) Our revenues are highly dependent on our hospitals in Hyderabad (Telangana). We are also significantly dependent on certain specialties for a majority of our revenues. Any impact on the revenues from these hospitals or earnings from our top specialties could materially affect our business, financial condition, results of operations and cash flows.
- 4) We have ceased operations at some of our facilities in the past, and we may continue to do so in the future.
- 5) One of our hospital buildings taken on lease, KIMS Kondapur, does not possess the requisite occupancy certificate from the relevant municipal authority and fire NoC from Telangana State Disaster Response and Fire Services Department. We may be subject to adverse regulatory action and may be required to vacate this facility, which may materially and adversely affect our business, reputation and financial condition.

## SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

### A. Total number of outstanding litigations/ regulatory action against the Company and amount involved:

Type of Proceedings	No. of cases	Amount involved (in ₹ million)*
Litigation against our Company	-	-
Criminal proceedings	4	14.00
Tax matters	-	-
a. Direct tax	Nil	Nil
b. Indirect tax	10	90.62
Actions by statutory and regulatory authorities	Nil	Nil
Other pending litigation	3	257.19
<b>Total</b>	<b>17</b>	<b>361.81</b>

\*to the extent quantifiable

### B. Top 5 material outstanding litigations / regulatory action against the Company:

Sr. no.	Particulars	Litigation filed by	Current Status	Amount involved (in ₹ million)*
1	The Drugs Inspector, Marredpally Zone (Sales), Secunderabad, filed a complaint before the XI Additional Chief Metropolitan Magistrate Court, Secunderabad against Dr. Bhaskara Rao Bollineni, alleging stocking of drugs for sale on unlicensed premises at our Secunderabad hospital. However, an interim stay order was later granted by the High Court, Hyderabad vide order dated April 12, 2016. For further details, please see page 351 of the RHP.	D. Swetha Bindu, Drugs Inspector, Marredpally Zone (Sales), Secunderabad	Pending before the High Court, Hyderabad	-
2	A first information report ("FIR") was filed by the brother of deceased patient under Section 304A of the Indian Penal Code, 1860 against the management and the doctors of our Company at that time. Later, the police filed a charge sheet against Dr. Bhaskara Rao Bollineni, Dr. Sharath Kumar Putta and the management of our Company. Additionally, the deceased patient's wife has also filed a consumer complaint before the Telangana State Consumer Disputes Redressal Commission, Hyderabad, on November 14, 2017, alleging negligence and deficiency in medical service. For further details, please see page 351 of the RHP.	Kishan Reddy Junnuthula	Pending before the XI Additional Chief Metropolitan Magistrate, Secunderabad and Telangana State Consumer Disputes Redressal Commission, Hyderabad	5.00
3	U. Pundareekudu, a patient who developed certain complications after surgery at our Secunderabad hospital, filed an FIR against Dr. Bhaskara Rao Bollineni, alleging, amongst others, criminal breach of trust and cheating. Subsequently, the police filed a charge sheet on April 16, 2018. For further details, please see page 352 of the RHP.	U. Pundareekudu	Pending before the XXII Additional Metropolitan Magistrate, Secunderabad	-



## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

4	Gajula Rama Murthy (“Complainant”), who developed certain complications after surgery at our Secunderabad hospital, filed an FIR against Dr. Sujeeth Kumar Vidiyala and the management of our Company for criminal negligence. The Complainant also filed a consumer complaint dated September 19, 2018 before the Telangana State Consumer Disputes Redressal Commission, Hyderabad, alleging negligence and deficiency in medical service. For further details, please see page 352 of the RHP.	Gajula Rama Murthy	Pending before the Ramgopalpet Police Station, Hyderabad and Telangana State Consumer Disputes Redressal Commission, Hyderabad	9.00
5	The relatives of the deceased Patient, filed a complaint before the National Consumer Disputes Redressal Commission, New Delhi against, amongst others, our Company, and Dr. Sujit Kumar Vidiyala, a neurology surgeon at our Secunderabad hospital alleging, amongst others, negligence in consultation. For further details, please see page 352 of the RHP.	Dr. Masaram Ranjana	Pending before the National Consumer Disputes Redressal Commission, New Delhi	235.01

\*to the extent quantifiable

For further details, see “Outstanding Litigation and Material Developments” beginning on page 351 of the RHP.

### C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action:

Sr. no.	Particulars	Current Status
1	Our Company, Dr. Bhaskara Rao Bollineni, Krishnaiah Bollineni and Sambasiva Rao Mayeni (“Applicants”) filed an application dated June 10, 2017 before the Regional Director, South East Region, Hyderabad (“RD”) / National Company Law Tribunal, Hyderabad praying for condonation and compounding of contravention of Section 67(3) of the Companies Act, 1956. The RD vide its order dated June 23, 2017 compounded the aforementioned offence and levied a compounding fee of ₹ 5,000 on each of the Applicants. Further, in relation to the Offence, our Company has completed the process of exit offer as directed by SEBI. For further details, please see page 354 of the RHP.	There are no actions pending against the Applicants in relation to the Offence
2	Our Promoters, Dr. Bhaskara Rao Bollineni, Dr. Abhinay Bollineni and Adwik Bollineni were the promoters of APL, which was previously listed on HSEL and MSEL, that were de-recognised as stock exchanges and then placed on the dissemination board of NSE. While APL was on the dissemination board, NSE decided to freeze the demat accounts of the directors and promoters of, amongst other companies, APL with effect from June 22, 2018. Subsequently, APL provided an exit opportunity to its public shareholders and was removed from the dissemination board of NSE with effect from September 18, 2018. The demat accounts of our Promoters mentioned above were subsequently unfrozen. For further details, please see page 354 of the RHP.	There are no actions pending against Dr. Bhaskara Rao Bollineni, Dr. Abhinay Bollineni and Adwik Bollineni in respect of their association with APL.

### D. Brief details of outstanding criminal proceedings against Promoters:

Sr. no.	Particulars*	Litigation filed by	Current Status	Amount involved (in ₹ million)
1	Following receipt of a complaint alleging that certain hospitals including Bollineni Super Specialty Hospital, Nellore (hospital owned by BRMH) are involved in fraudulent activities of raising mediclaims, the Central Bureau of Investigation, Hyderabad instituted a criminal case on July 12, 2007 against Dr. Bhaskara Rao Bollineni, BRMH and others. Dr. Bhaskara Rao Bollineni and BRMH instituted quashing petitions before the High Court, Hyderabad against this case (“Matter”). The Matter was last heard by the High Court, Hyderabad on March 6, 2020 pursuant to which an order dated March 6, 2020 (“Interim Order”) was passed, granting extension of four weeks on the stay. Subsequently, an interim application has been filed to grant further extension. For further details, please see page 353 of the RHP.	M/s. United India Insurance Co. Ltd.	Pending before The High Court, Hyderabad	-

\*Additionally, certain criminal proceedings initiated against our Company, also involve Dr. Bhaskara Rao Bollineni, one of the Promoter of our Company in his capacity as the Managing Director of our Company. For details, see “Outstanding Litigation and Material Developments - Criminal proceedings against our Directors” on page 354 of the RHP and “Top 5 material outstanding litigations / regulatory action against the Company” page 7 of this Abridged Prospectus.

## ANY OTHER IMPORTANT INFORMATION AS PER BRLMs / COMPANY

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be ‘qualified institutional buyers’ (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from the registration requirements of the U.S. Securities Act and (b) outside the United States in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are made.

## DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules made or guidelines or regulations issued by the GoI or the guidelines or regulations issued by the SEBI, established under Section 3 of the SEBI Act, 1992 as the case may be, have been complied with and no statement made in the RHP is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act 1956, the Securities Contracts (Regulation) Rules, 1957, the SEBI Act, 1992 or the rules made or guidelines or regulations issued thereunder, as the case may be. We further certify that all the statements in the RHP are true and correct.

## DECLARATION BY THE SELLING SHAREHOLDERS

We hereby confirm that all statements, disclosures and undertakings made by us in the RHP in relation to us, as an Selling Shareholder respectively and our portion of the Offered Shares, are true and correct. We assume no responsibility for any other statements, disclosures and undertakings including statements made or confirmed by or relating to the Company or any other Selling Shareholders, or any other person(s) in the RHP.



**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK**

**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK**

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

### BIDDER'S UNDERTAKING FOR REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid Cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

### INSTRUCTIONS FOR FILLING UP THE REVISION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an Offer' and not 'an Offer'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid Cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your Bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, RIBs who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, RIBs who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the First Bidder is required to sign the Bid Cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
  - QIBs and Non-Institutional Investors cannot use UPI Mechanism to apply.
  - For RIBs applying using UPI.**
    - Please ensure that your Bank is offering UPI facility for Public Offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) RIBs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
    - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - RIBs Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN.

For further details, see "Offer Procedure" on page 381 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof.

### OFFER STRUCTURE

Particulars	Eligible Employees <sup>a</sup>	QIBs <sup>b</sup>	Non-Institutional Bidders	Retail Individual Bidders
Number of Equity Shares available for Allotment/ allocation <sup>a(2)</sup>	Not more than [●] Equity Shares	Not less than [●] Equity Shares	Not more than [●] Equity Shares available for allocation or Net Offer less allocation to QIB Bidders and RIBs	Not more than [●] Equity Shares available for allocation or Net Offer less allocation to QIB Bidders and Non Institutional Bidders
Percentage of Offer size available for Allotment/ allocation	The Employee Reservation Portion shall constitute up to [●]% of the Offer Size	Not less than 75% of the Net Offer shall be Allotted to QIB Bidders. However, up to 5% of the QIB Portion (excluding Anchor Investor Portion) will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be available for allocation to QIBs	Not more than 15% of the Net Offer or the Net Offer less allocation to QIB Bidders and RIBs shall be available for allocation	Not more than 10% of the Net Offer or the Net Offer less allocation to QIB Bidders and Non-Institutional Bidders available for allocation
Basis of Allotment if respective category is oversubscribed <sup>a</sup>	Proportionate <sup>a</sup> ; unless the Employee Reservation Portion is undersubscribed, the value of allocation to an Eligible Employee shall not exceed ₹ 200,000.00. In the event of undersubscription in the Employee Reservation Portion, the unsubscribed portion may be Allocated, on a proportionate basis, to Eligible Employees for a value exceeding ₹ 200,000.00, subject to total Allotment to an Eligible Employee not exceeding ₹ 500,000.00	Proportionate as follows (excluding the Anchor Investor Portion): (a) At least [●] Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and (b) [●] Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above.  Up to 60% of the QIB Portion Equity Shares may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price.	Proportionate	Allotment to each RIB shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares if any, shall be Allotted on a proportionate basis. For further details, see "Offer Procedure" on page 381 of the RHP.
Minimum Bid	[●] Equity Shares	Such number of Equity Shares and in multiples of [●] Equity Shares that the Bid Amount exceeds ₹200,000.00	Such number of Equity Shares in multiples of [●] Equity Shares that the Bid Amount exceeds ₹200,000.00	[●] Equity Shares and in multiples of [●] Equity Shares thereafter
Maximum Bid	Such number of Equity Shares in multiples of [●] Equity Shares, so that the Bid Amount does not exceed ₹ 500,000.00	Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Offer, subject to applicable limits	Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Offer (excluding the QIB Portion), subject to limits applicable to Bidder	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid Amount does not exceed ₹200,000.00
Mode of Allotment	Compulsorily in dematerialised form			
Bid Lot	[●] Equity Shares and in multiples of [●] Equity Shares thereafter			
Allotment Lot	A minimum of [●] Equity Shares and in multiples of one Equity Share thereafter			
Trading Lot	One Equity Share			
Who can apply <sup>(3)</sup>	Eligible Employees	Public financial institutions as specified in Section 2(72) of the Companies Act 2013, scheduled commercial banks, Mutual Funds, FPIs (other than individuals, corporate bodies and family offices), VCFs, AIFs, FVCIs registered with SEBI, multilateral and bilateral development financial institutions, state industrial development corporation, insurance companies registered with IRDAI, provident funds (subject to applicable law) with minimum corpus of ₹250 million, pension funds with minimum corpus of ₹250 million National Investment Fund set up by the GoI, the insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important NBFCs.	Resident Indian individuals, Eligible NRIs, HUFs (in the name of the karta), companies, corporate bodies, scientific institutions societies and trusts, FPIs who are individuals, corporate bodies, family offices which are re-categorised as Category II FPIs and registered with SEBI.	Resident Indian individuals, Eligible NRIs and HUFs (in the name of karta)
Terms of Payment	<b>In case of Anchor Investors:</b> Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids <sup>(4)</sup> <b>In case of all other Bidders:</b> Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form.			
Mode of Bid	Only through the ASBA process (except for Anchor Investors)			

<sup>a</sup> Assuming full subscription in the Offer.

<sup>b</sup> Eligible Employees Bidding in the Employee Reservation Portion can Bid up to a Bid Amount of ₹ 500,000.00. However, a Bid by an Eligible Employee in the Employee Reservation Portion will be considered for allocation, in the first instance, for a Bid Amount of up to ₹ 200,000.00. In the event of under-subscription in the Employee Reservation Portion the unsubscribed portion will be available for allocation and Allotment, proportionately to all Eligible Employees who have Bid in excess of ₹ 200,000.00, subject to the maximum value of Allotment made to such Eligible Employee not exceeding ₹ 500,000.00. The unsubscribed portion, if any in the Employee Reservation Portion can also Bid in the Net Offer and such Bids will not be treated as multiple Bids subject to applicable limits. Further, an Eligible Employee Bidding in the Employee Reservation Portion shall be added back to the Net Offer. In case of under-subscription in the Net Offer, spill-over to the extent of such under-subscription shall be permitted from the Employee Reservation Portion.

- Our Company may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. For details, see "Offer Procedure" on page 381 of the RHP.
- Subject to valid Bids being received at or above the Offer Price. This is an Offer in terms of Rule 19(2)(b) of the SCRR and under the SEBI ICDR Regulations, in compliance with Regulation 6(2) of the SEBI ICDR Regulations.
- If the Bid is submitted in joint names, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the depository account held in joint names. The signature of only the first Bidder would be required in the Bid cum Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders. Bidders will be required to confirm and will be deemed to have represented to our Company, the Selling Shareholders, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.
- Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Offer Price shall be payable by the Anchor Investor Pay-In-Date as indicated in the CAN.



**COMMON BID  
REVISION  
FORM**

**KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED - INITIAL PUBLIC OFFER - R**  
Registered and Corporate Office: D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana 500 003, India; Tel: +91 40 4418 6000;  
Website: www.kimshospitals.com; Contact Person: Umashankar Mantha, Company Secretary and Compliance Officer;  
E-mail: cs@kimshospitals.com; Corporate Identity Number: U55101TG1973PLC040558

FOR RESIDENT INDIAN INVESTORS INCLUDING  
RESIDENT QIBs, NON-INSTITUTIONAL BIDDERS,  
RETAIL INDIVIDUAL BIDDERS AND ELIGIBLE NRIs  
APPLYING ON A NON-REPATRIATION BASIS



To,  
The Board of Directors  
KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

**100% BOOK BUILT OFFER**  
ISIN : INE967H01017  
LEI: 254900JA6LS4UY2ZCR81

**Bid cum  
Application  
Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE	REGISTERED BROKER / SCSB / CDP / RTA STAMP & CODE	<b>1. NAME &amp; CONTACT DETAILS OF SOLE / FIRST BIDDER</b> Mr. /Ms./M/s. _____ Address _____ _____ Email _____ Tel. No. (with STD code) / Mobile _____
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	
		<b>2. PAN OF SOLE / FIRST BIDDER</b> _____
		<b>3. BIDDER'S DEPOSITORY ACCOUNT DETAILS</b> <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

**PLEASE CHANGE MY BID**

4. FROM (AS PER LAST BID OR REVISION)													
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only)				
	(In Figures)								(In Figures Only)				
	8	7	6	5	4	3	2	1	Bid Price	Retail Discount	Net Price	"Cut-off" (Please ✓ tick)	
Option 1													
(OR) Option 2													
(OR) Option 3													
5. TO (REVISED BID) (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")													
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only)				
	(In Figures)								(In Figures Only)				
	8	7	6	5	4	3	2	1	Bid Price	Retail Discount	Net Price	"Cut-off" (Please ✓ tick)	
Option 1													
(OR) Option 2													
(OR) Option 3													

6. PAYMENT DETAILS [IN CAPITAL LETTERS]										PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/>									
Additional Amount Blocked (₹ in figures) _____ (₹ in words) _____																			
<b>ASBA</b> Bank A/c No. _____ Bank Name & Branch _____ OR UPI ID (Maximum 45 characters) _____																			
I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN ALONG WITH THE BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM GIVEN OVERLEAF.																			
7A. SIGNATURE OF SOLE/ FIRST BIDDER										7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)									
Date : _____, 2021										I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.									
										1) _____									
										2) _____									
										3) _____									
										MEMBERS OF THE SYNDICATE / SUB - SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)									

TEAR HERE

	<b>KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED</b> <b>BID REVISION FORM - INITIAL PUBLIC OFFER - R</b>										<b>Acknowledgement Slip for</b> <b>Members of the Syndicate / Sub-Syndicate</b> <b>Member / Registered Broker / SCSB /</b> <b>CDP / RTA / Agent</b>										<b>Bid cum</b> <b>Application</b> <b>Form No.</b>									
	DPID / CLID										PAN of Sole / First Bidder																			
	Additional Amount Blocked (₹ in figures) _____ ASBA Bank A/c No./UPI ID _____										Stamp & Signature of SCSB Branch																			
	Bank Name & Branch _____																													
Received from Mr./Ms./M/s. _____										Telephone / Mobile _____ Email _____																				

TEAR HERE

<b>KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - R</b>	Option 1    Option 2    Option 3			Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent										Name of Sole / First Bidder									
	No. of Equity Shares			_____										_____									
	Bid Price																						
	Additional Amount Blocked (₹ in figures)			<b>Acknowledgement Slip for Bidder</b>										<b>Bid cum</b> <b>Application</b> <b>Form No.</b>									
ASBA Bank A/c No. /UPI ID _____ Bank Name & Branch _____																							

Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

TEAR HERE - PLEASE FILL IN BLOCK LETTERS - TEAR HERE - Printed by : Orient Press Ltd.